Rifagut, also known by the generic name rifaximin, is a medicine often used to treat hepatic encephalopathy (HE). Hepatic encephalopathy is a major neurological complication that develops in people with advanced liver disease, such as cirrhosis, when toxins that the liver typically processes build in the bloodstream and impair brain function. Rifagut works by inhibiting the growth of ammonia-producing bacteria in the gut, which is a major factor to the development of hepatic encephalopathy. Rifagut’s benefits include its capacity to effectively manage the symptoms of hepatic encephalopathy, such as confusion, disorientation, difficulties concentrating, and behavioral abnormalities. By addressing the underlying cause of hepatic encephalopathy, Rifagut improves cognitive function and quality of life in patients.